When Wayne mentioned the immunotherapies partnership he seemed to allude to potentially a majority sale.
He said we'll have an equity stake which sounds to me like less than a controlling stake.
Happy with that. Drug development is just too expensive and lead times are too long. So uncertain as well. Iterating new adapt products sounds like a much smarter play.
Wonder how Fraser is feeling about it. Could potentially end up working to make money for big pharma again.
When Wayne mentioned the immunotherapies partnership he seemed...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$22.75 |
Change
-0.250(1.09%) |
Mkt cap ! $437.0M | |||
| Open | High | Low | Value | Volume |
| $23.45 | $23.45 | $22.50 | $115.8K | 5.075K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 65 | $22.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $23.15 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$22.79 |
Change
-0.250 ( 1.13 %) |
||||
| Open | High | Low | Volume | ||
| $22.80 | $22.90 | $22.75 | 138 | ||
| Last updated 14.50pm 26/04/2024 ? | |||||
| AVR (ASX) Chart |